Endocrine Society <http://www.endo-society.org> Molecular Endocrinology </>
HOME </> 	HELP </help/> 	FEEDBACK </cgi/feedback> 	SUBSCRIPTIONS
</subscriptions/> 	ARCHIVE </contents-by-date.0.shtml> 	SEARCH
</search.dtl> 	


  Instructions to Authors for /Molecular Endocrinology/


    Expectation of Ethical Conduct

The Endocrine Society's mission is to advance excellence in
endocrinology and be an integrative force in scientific research and
medical practice. Such progress depends on integrity in the conduct of
scientific research and truthful representation of findings. Specific
guidelines regarding the Society's expectations for ethical conduct can
be found in the Code of Ethics of The Endocrine Society and the Ethical
Guidelines for Publications of Research. The journal editors and
publication oversight committees of The Endocrine Society are dedicated
to upholding high ethical standards in its publications and expect
authors and reviewers to do the same.


    Purpose and Scope

/Molecular Endocrinology/ publishes papers that use a molecular approach
to study the mechanism of action of hormones and related substances and
their regulation.

/Molecular Endocrinology/ is a journal devoted to rapid publication of
papers pertaining to the molecular mechanisms by which hormones and
related compounds regulate function. The journal will promote the
interaction of disciplines by accepting papers in fields studying
processes with overlapping mechanisms, including hormones, growth
factors, oncogenes and their products, growth inhibitory factors, ions,
lymphokines, etc.


    General Information

Authors should submit their full manuscript directly through the Rapid
Review system, at which time it will undergo an initial prescreening.
Every effort will be made to provide prompt review and rapid return of
manuscripts to authors. Manuscripts are published on The Endocrine
Society's Journals Online web site as Rapid Electronic Publications
(REP) at http://mend.endojournals.org/rep.shtml about two (2) weeks
after final acceptance, and in print about three (3) months after final
acceptance.


    Manuscript Categories

The following three types of articles will be considered for publication:

(1) The bulk of the journal will be comprised of *regular research
papers* based on new data, previously unpublished in reviewed journals
or unreviewed publications. These papers may be of any length; however,
brevity is no contraindication for submission.

(2) Second, *minireviews* and *overviews* may be published from time to
time. If an author wishes to suggest a topic for a minireview, he or she
first should contact the editorial office of /Molecular Endocrinology/
to ascertain its appropriateness.

(3) Third, *research resource articles* are meant to present the most
current and important work done with microarrays, proteomics, genomics,
metabolomics, structural biology, computational biology, and computer
programs, as well as other relevant research data sets. These
manuscripts are subject to the same stringent peer review as our
original research articles and minireviews. In structure, they will
differ from original research articles in that they: 1) will not be
required to contain the same mechanistic focus, and 2) generally will
not exceed a total of four pages in length. Acceptance of manuscripts
will be contingent on scientific content, broad appeal, and usefulness
to studies in the area of molecular endocrinology. Authors are
encouraged to make use of our online Supplemental Data feature to
present further work that supports the content of the Research Resource
submissions. All manuscripts are treated as confidential material during
the review process.


    Manuscript Submission Procedures

Please submit your manuscript to /Molecular Endocrinology/ through the
Rapid Review system at the following site: http://mend.endojournals.org/.

Note that your author account will be the same for /Endocrinology/,
/Molecular Endocrinology/, /The Journal of Clinical Endocrinology &
Metabolism/, and /Endocrine Reviews/. Authors submitting manuscripts for
publication in /Molecular Endocrinology/ are submitting their manuscript
to The Endocrine Society Central Journals Office whose database is
accessible to the Editors-in-Chief of all Endocrine Society journals.

All submissions MUST INCLUDE:
1. Cover letter. Submitted manuscripts must be accompanied by a cover
letter that describes the study's unique contribution to the field and
explains why it is appropriate for publication in /Molecular
Endocrinology/. Specifically, the editors would like to know what unique
mechanistic contributions and insights are offered by the paper, as well
as their physiological relevance. Authors should also provide a list of
possible reviewers, and they may request that specific reviewers not be
used. Authors must also indicate that they are submitting supplemental
data when appropriate.
2. Completed Copyright Assignment & Affirmation of Originality form,
which is available at http://mend.endojournals.org/misc/origcopy.pdf
3. Completed Disclosure of Potential Conflict of Interest form.
IMPORTANT: The *corresponding author* is expected to gather EACH
AUTHOR'S completed disclosure form and fax them, together, to the
editorial office along with the Author Disclosure Summary. Do not fax
them individually. Revised manuscripts WILL NOT be processed until all
signatures and the summary are received.


    Manuscript Preparation


      General Format

The Journal requires that all manuscripts be submitted in a 2-column
# format that follows these guidelines: Format text from the Introduction
through the Acknowledgements in two single-spaced columns.
# All text should be single spaced with 1-inch margins on both sides using
11-point type in Times Roman font.
# The abstract, references and legends should be set in 1 column.
# Authors are encouraged to cite primary literature rather than review
articles in order to give credit to those who have done the original
studies.
# All tables and figures must be placed after the text and must be
labeled. Submitted papers must be complete, including the title page,
abstract, figures, and tables. Papers submitted without all of these
components will be placed on hold until the manuscript is complete.


      Title Page

The title page must include the following:
# Full title (a concise statement of the article's major contents)
# Abbreviated title of not more than 40 characters for page headings
# Authors' names and institutions. At least one person must be listed as
an author; no group authorship without a responsible party is allowed. A
group can be listed in the authorship line, but only on behalf of a
person or persons. All group members not listed in the authorship line
must be listed in the Acknowledgments section.
# *All papers produced with NIH support must include the paragraph
indicated in the The Endocrine Society NIH statement.*
# Corresponding author's address, telephone and fax numbers, and e-mail
address
# Name and address of person to whom reprint requests should be addressed
# Key words to support indexing and information retrieval
# Any grants or fellowships supporting the writing of the paper
# Disclosure summary (see Disclosure of Potential Conflict of Interest form)


      Abstract

Do not exceed 250 words
# Briefly describe in complete sentences the purpose of the investigation,
the methods used, the results obtained, and the principal conclusions
# Do not refer to the text or references
# Write the abstract with a general audience in mind


      Introduction

The article should begin with a brief introductory statement that places
the work to follow in historical perspective and explains its intent and
significance.


      Results and Discussion

The Results section should briefly present the experimental data in
text, tables, and/or figures. For details on preparation of tables and
figures, see below. The Discussion should focus on the interpretation
and significance of the findings with concise objective comments that
describe their relation to other work in that area. The Discussion
should not reiterate the Results.


      Materials and Methods

These should be described and referenced in sufficient detail for other
investigators to repeat the work. The source of hormones, unusual
chemicals and reagents, and special pieces of apparatus should be
stated. For modified methods, only the modifications need be described.


      Acknowledgments

The Acknowledgments section should include the names of those people who
contributed to a study but did not meet the requirements for authorship.
The corresponding author is responsible for informing each person listed
in the Acknowledgments section that they have been included and
providing them with a description of their contribution so they know the
activity for which they are considered responsible.


      References

References to the literature should be cited in numerical order (in
parentheses) in the text and listed in the same numerical order at the
end of the manuscript on a separate sheet or sheets. There must be only
one reference to a number. The number of references cited should be kept
to a reasonable minimum; to this end, appropriate recent reviews should
be cited whenever possible.

Examples of the reference style that should be used are given below.
Further examples will be found in the articles describing the Uniform
Requirements for Manuscripts Submitted to Biomedical Journals (Ann
Intern Med. 1988; 208:258-265, Br Med J. 1988; 296:401-405). The titles
of journals should be abbreviated according to the style used in the
/Index Medicus/.

If the citation formats described here do not match the formats provided
in your reference manager program, please visit the software producer's
web site for updates.

Journal articles and abstracts: List /all/ authors. The citation of
unpublished observations, of personal communications, and of manuscripts
in preparation or submitted for publication is not permitted in the
bibliography. Such citations should be inserted at appropriate places in
the text, in parentheses and without serial number, or be presented in
the footnotes. The citation of manuscripts in press (i.e., accepted for
publication) is permitted in the bibliography; the name of the journal
in which they appear must be supplied. If references to personal
communications are made, authors are encouraged to keep written proof of
the exchange. If it is necessary to cite an abstract because it contains
substantive data not published elsewhere, it must be designated at the
end of the reference [e.g., 68:313 (Abstract)]. *The author is
responsible for the accuracy of references.*

/Books/: List /all/ authors or editors.

/Sample References/

   1. *Binoux M, Hossenlopp P* 1986 Insulin-like growth factor (IGF) and
      IGF-binding proteins: comparison of human serum and lymph. J Clin
      Endocrinol Metab 67:509-514
   2. *MacLaughlin DT, Cigarros F, Donahoe PK* 1988 Mechanism of action
      of Mullerian inhibiting substance. Program of the 70th Annual
      Meeting of The Endocrine Society, New Orleans, LA, 1988, p 19
      (Abstract P1-21)
   3. *Bonneville F, Cattin F, Dietemann J-L* 1986 Computed tomography
      of the pituitary gland. Heidelberg: Springer-Verlag; 15-16
   4. *Burrow GN* 1987 The Thyroid: nodules and neoplasia. In: Felig P,
      Baxter JD, Broadus AE, Frohman LA, eds. Endocrinology and
      metabolism. 2nd ed. New York: McGraw-Hill; 473-507

For general aid in the preparation of manuscripts, authors should
consult: CBE Style Manual: A Guide for Authors, Editors and Publishers.
5th ed. Bethesda, MD: Council of Biology Editors; 1983


      Tables

Tables must be constructed as simply as possible and be intelligible
without reference to the text. Each table must have a concise heading. A
description of experimental conditions may appear together with
footnotes at the foot of the table. Tables must not simply duplicate the
text or figures. The width of the table must be designed to occupy one
or two journal columns, with no more than four table columns or 8-10
table columns, respectively.


      Figures and Legends

Please review the detailed instructions for preparing digital art at
http://art.cadmus.com/da/index.jsp. E-mail queries can be sent to
digitalart@cadmus.com <mailto:digitalart@cadmus.com>. All figures must
display the figure number.

/Sizing the figure/: The author is responsible for providing digital art
that has been properly sized, cropped, and has adequate space between
images. Plan the size of the figure to fill 1, 1.5, or 2 columns in the
printed journal (see chart below for dimensions). In most cases, figures
should be prepared for 1-column width. Produce original art at the size
it should appear in the printed journal. (Note for PowerPoint users: The
sizing instructions do not apply if you are submitting PowerPoint files
for print production in E-Review. On the submission page, check boxes to
indicate that the figures are the correct size and resolution.)

1 column = 18 picas, 7.5 cm, 3.0 in

1.5. columns = 30 picas, 12.5 cm, 5.0 in

2 columns = 38 picas, 16.0 cm, 6.5 in

/Lettering/: At 100% size, no lettering should be smaller than 8 point
(0.3 cm high) or larger than 12 point (0.4 cm high). Use bold and solid
lettering. Lines should be thick, solid, and no less than 1-point rule.
Avoid the use of reverse type (white lettering on a darker background).
Avoid lettering on top of shaded or textured areas. Titles should be
clear and informative. Keep wording on figures to a minimum, and confine
any explanation of figures to their separate page legends. Label only
one vertical and one horizontal side of a figure. /Freehand lettering or
drawing is unacceptable/.

/Special requirements for 4-color art/: Save files in CMYK mode
(cyan-magenta-yellow-black). Color saturation of the shadow portion
cannot exceed 280% (%cyan + %magenta + %yellow + %black cannot exceed
280%).

/Shading/: Avoid the use of shading, but if unavoidable, use a coarse
rather than a fine screen setting (80-100 line screen is preferred).
Avoid 1-20% and 70-99% shading; make differing shades vary by at least
20%, i.e., 25%, 45%, 65%. Instead of shading, denote variations in
graphs or drawings by cross-hatching; solid black; or vertical,
horizontal, or diagonal striping. Avoid the use of dots.

Grouped figures: For grouped figures, indicate the layout in a diagram.
Place grouped figures so that they can be printed in 1-column width with
uniform margins. Indicate magnification in the legends and by internal
reference markers in the photographs. Their length should represent the
fraction or multiple of a micrometer, appropriate to the magnification.

/Graphs/: Graphs with axis measures containing very large or small
numbers should convert to easily readable notations. Example: For an
ordinate range of "counts per minute" values from 1,000 to 20,000, the
true value may be multiplied by 10^-3 (scale would read from 1 to 20)
and the ordinate axis display "cpm (x10^-3 )." Similarly, for a
Scatchard plot with values ranging from 0.1 to 2 femtomolar (10^-15 m),
the scale may run from 0.1 to 2 with the abscissa labeled "m (x10^-15
)." /Three-dimensional bar graphs will not be published if the
information they refer to is only two-dimensional./


      Supplemental Data

Supplemental Data allows authors to enhance papers in /Molecular
Endocrinology/ by making additional substantive material available to
readers. Supplemental Data may take the form of figures, tables,
datasets, derivations, or videos, and is published only in /Molecular
Endocrinology/ online; it does not appear in the printed version of the
journal. Authors who wish to include Supplemental Data should state so
in the cover letter when the manuscript is submitted.

Supplemental Data files should be submitted through Rapid Review at the
time of manuscript submission and will be reviewed along with the
manuscript. The files should be uploaded in the field marked "Upload
Supplemental Data Files", and should NOT be attached with the manuscript
and figure files. Authors should refer to the Supplemental Data in the
manuscript at an appropriate point in the text or figure/table legend.

The file formats listed below may be used for Supplemental Data. Provide
a brief description of each item in a separate HTML or Word file
(/i.e./, figure or table legends, captions for movie or sound clips,
etc.). Do not save figure numbers, legends, or author names as part of
an image. File sizes should not exceed 5 MB. Images should not exceed
500 pixels in width or height. Do not use tabs or spaces for Word or
WordPefect tables; please use the table functions available within these
word processing programs to prepare tables. For web pages, provide a
complete list of files and instructions for creating directories.

.htm, HTML*
.jpg, JPEG image*
.gif, Graphical image
.pdf, Adobe Portable Document Format
.xls, MS Excel Spreadsheet
.mov, Quick Time
.wav, Sound
.doc, MS Word 6 documents**
.txt, Plain ASCII*

*These files can be viewed directly on standard web browsers.
**MS Word may be used for text only.


      Units of Measure

Results should be expressed in metric units. Système Internationale (SI
units) must be added in parentheses. Temperature should be expressed in
degrees Celsius (/e.g./, 28 C) and time of day using the 24-hour clock
(/e.g./, 0800 h, 1500 h). Do not express molecular weight in daltons.
Molecular weight is considered to be the relative molecular mass of a
substance, /i.e./, the ratio of the mass of one molecule of the
substance to 1/12 of the mass of one atom of carbon 12. Therefore,
molecular weight is dimensionless. The dalton is a unit of mass
equivalent to 1/12 of the mass of one atom of p1 carbon 12.


    Editorial Policies and Guidelines


      Prior Publication

Failure to notify the editor that some results in the manuscript are
being or have been previously published will result in placement of a
notice in the journal that the authors have violated the Ethical
Guidelines for Publication of Research in The Endocrine Society
Journals. The journal publishes original research and review material.
Material previously published in whole or in part shall not be
considered for publication. This includes materials published in any
form of mass communication. At the time of submission, authors must
divulge in their cover letter all prior publications or postings of the
material in any form of media. Abstracts or posters displayed for
colleagues at scientific meetings need not be reported. Other postings
of any part of the submitted material on web pages, as well as those
essential for participation in required registries will be evaluated by
the Editor-In-Chief, who shall determine if those postings are material
enough to constitute prior publication.


      Authorship Criteria

An author should have participated in either the conception or planning
of the work, the interpretation of the results and the writing of the
paper. An acknowledgment accompanying the paper is appropriate
recognition for others who have contributed to a lesser extent, e.g.,
provision of clones, antisera or cell lines, or reading and reviewing
manuscripts in draft. The signature of each author on the Affirmation of
Originality and Copyright Release form that must be submitted with the
manuscript indicates that all authors have had a part in the writing and
final editing of the report, all have been given a copy of the
manuscript, all have approved the final version of the manuscript, and
all are prepared to take public responsibility for the work, sharing
responsibility and accountability for the results.


      Obligations of Reviewers

The critical and confidential review of manuscripts is an essential
element of research publications. Every scientist has an obligation to
contribute to the peer review process by serving as a reviewer. Among
the obligations of reviewers is the commitment to providing an expert,
critical, and constructive scientific and literary appraisal of research
reports in their fields of knowledge, skills, and experience in a fair
and unbiased manner. In order to facilitate the prompt sharing of
scientific results, it is also the obligation of each reviewer to
complete their assignments promptly, within the editor's deadline.
Should a delay in their review occur, the reviewer has the obligation to
notify the editor at once.

Reviewers should not review a manuscript if: 1) they do not think that
they are competent to assess the research described, 2) they believe
there is a conflict of interest or personal or professional relationship
with the author(s) that might bias their assessment of the manuscript,
or (3) there is any other situation that could bias their review.
Employment at the same institution as one of the authors does not
automatically represent a conflict. Having previously reviewed the
article for another journal does not disqualify a reviewer, although the
editor should be informed so the reviewer's perspective can be
considered. In circumstances when reviewers need to recuse themselves,
they should notify the editor promptly, preferably with an explanation.
If reviewers are uncertain whether they should recuse themselves, they
should consult with the editor.

The reviewer should strive to provide accurate, detailed, and
constructive criticisms, and the review should be supported by
appropriate references, especially if unfavorable. The reviewer should
also note whether the work of others is properly cited. If the reviewer
notes any substantial resemblance of the manuscript being reviewed to a
published paper or to a manuscript submitted at the same time to another
journal, they should promptly report this to the editor.

No part of the manuscript under review should ordinarily be revealed to
another individual without the permission of the editor. If a reviewer
consults a colleague on a particular point, this fact, and the name of
the collaborator or consultant, should be reported to the editor,
preferably in advance. With these exceptions, a reviewer must obtain
through the editor written permission from the authors to use or
disclose any of the unpublished content of a manuscript under review.


      Experimental Subjects

To be considered, all clinical investigations described in submitted
manuscripts must have been conducted in accordance with the guidelines
in *The Declaration of Helsinki* <http://www.wma.net> and must have been
formally approved by the appropriate institutional review committees or
its equivalent. All manuscripts must indicate that such approval was
obtained and that informed consent was obtained from subjects in all
experiments involving humans. The study populations should be described
in detail. In many studies details of age, race, and sex are important.
However, subjects must be identified only by number or letter, not by
initials or names. Photographs of patients' faces should be included
only if scientifically relevant. Authors must obtain written consent
from the patient for use of such photographs. For further details, see
the Ethical Guidelines.


      Experimental Animals

A statement confirming that all animal experimentation described in the
submitted manuscript was conducted in accord with accepted standards of
humane animal care, as outlined in the Ethical Guidelines, should be
included in the manuscript.


      Manuscripts Reporting New Amino Acid or Nucleotide Sequence

Manuscripts reporting amino acid or nucleotide sequences of proteins
with sequences already known from other tissues or species will be
considered only if they provide new biological insight. Manuscripts
dealing with partial sequence data are not likely to be considered. The
Endocrine Society has established policy that deals with submission of
new protein or nucleic acid sequences. When a manuscript is accepted
that contains novel sequences, such sequences must be deposited in the
appropriate database (such as GenBank) and an accession number obtained
before the manuscript is sent to the printer. It is recommended that the
following statement containing the assigned accession number be inserted
as a footnote: "These sequence data have been submitted to the
DDBJ/EMBL/GenBank databases under accession number Ul2345."


      Manuscripts Reporting Novel Compounds

Manuscripts describing experiments with new compounds must provide their
chemical structures. For known compounds, the source and/or literature
reference to the chemical structure and characterization must be provided.


      Genomic and Proteomic Papers

We consider papers that use genomic or proteomic approaches to study
problems relevant to molecular endocrinology. We recognize that many of
these will not be hypothesis driven. Nevertheless, manuscripts that
utilize these approaches should go beyond cataloging and provide unique
insights into regulatory networks, mechanisms, or demonstrations of
biological function.

As a first step for standardizing presentation of gene expression
profiling data, we are now requiring that filtered raw data be submitted
as a supplement (see section on Supplemental Data) in a tab-delimited
format using spreadsheets such as Microsoft Excel. In presenting DNA
microarray data it is essential to clearly identify the platform
(/i.e./, Affymetrix Murine Genome U74v2 Set), thoroughly describe the
filtering criteria used to evaluate the raw data, and provide complete
references for the statistical methods used to analyze the data. The
supplemental data must accompany the original submission and can be
submitted electronically through E-Review. Specific examples of
supplemental data accompanying gene expression profiling manuscripts can
be found in the June 2002 issue of /Molecular Endocrinology/. In
addition to submitting supplemental data, we recommend that authors
submit the same data to the *Gene Expression Omnibus (GEO)*
<http://www.ncbi.nlm.nih.gov/geo/>. The National Institute of
Biotechnology Information, under the auspices of the National Library of
Medicine and NIH, has launched the GEO database to support the public
dissemination of gene expression data. GEO is intended to complement
in-house gene expression databases by acting as a tertiary, central data
distribution hub. More specific information regarding both the history
and submission requirements can be found in the web site cited above.

Proteomic papers that report molecular structures, whether based on
x-ray crystallography, NMR, or computational modeling, can be accepted
only after the structural coordinates have been deposited in the
*Protein Data Base* <http://www.biochem.ucl.ac.uk/~roman/procheck.html>.


      Validation of Data and Statistical Analysis

/Assay validation/: Bioassay and radioimmunoassay potency estimates
should be accompanied by an appropriate measure of the precision of
these estimates. For bioassays, these usually will be the standard
deviation, standard error of the mean, coefficient of variation, or 95%
confidence limits. For both bioassays and radioimmunoassays, it is
necessary to include data relating to within-assay and between-assay
variability. If all relevant comparisons are made within the same assay,
the latter may be omitted. Authors should be aware that the precision of
a measurement depends upon its position on the dose-response curve.

In presenting results for new assays, it is necessary to include data on
the following: 1) within-assay variability; 2) between-assay
variability; 3) slope of the dose-response curve; 4) mid-range of the
assay; 5) least-detectable concentration (concentration resulting in a
response two standard deviations away from the zero dose response); 6)
data on specificity; 7) data on parallelism of standard and unknown and
on recovery; and 8) comparison with an independent method for assay of
the compound. When radioimmunoassay kits are utilized or hormone
measurements are conducted in other than the authors' laboratories and
the assay is central to the study, data regarding performance
characteristics should be included.

/Pulse analysis/: Data from studies of pulsatile hormone secretion
should be analyzed using a validated, objective pulse detection
algorithm. The algorithm used should require that false-positive rates
of pulse detection be defined in relation to the measurement error of
the data set being analyzed, and the methods used to determine the
measurement error should be described. The author(s) also should
describe the methods used: 1) to deal with missing or undetectable
values; 2) to determine peak frequency, interpeak interval, and pulse
amplitude; and 3) For statistical comparisons of peak parameters.

/Data analysis/: It is the author's responsibility to document that the
results are reproducible and that the differences found are not due to
random variation. No absolute rules can be applied, but in general
quantitative data should be from no fewer than three replicate
experiments. Appropriate statistical methods should be used to test the
significance of differences in results. The term "significant" should
not be used unless statistical analysis was performed, and the
probability value used to identify significance (/e.g./, /P/ > 0.05)
should be specified.

When several t tests are employed, authors should be aware that nominal
probability levels no longer apply. Accordingly, the multiple t test,
multiple range test, or similar techniques to permit simultaneous
comparisons should be employed. Also, in lieu of using several t tests,
it is often more appropriate to utilize an analysis of variance (ANOVA)
to permit pooling of data, increase the number of degrees of freedom,
and improve reliability of results. Authors should use appropriate
nonparametric tests when the data depart substantially from a normal
distribution.

Analysis of variance tables should not be inserted in manuscripts. F
values with the degrees of freedom as subscripts together with the /P/
values are sufficient.

In presenting results of linear regression analyses, it is desirable to
show 95% confidence limits.

When data points are fitted with lines (as in Scatchard or
Lineweaver-Burk plots), the method used for fitting (graphical, least
squares, computer program) should be specified. If differences in slopes
and/or axis intercepts are claimed for plotted lines, these should be
supported by statistical analysis.

Useful references for statistical methods are McArthur, J. W., and T.
Colten (eds.), /Statistics in Endocrinology/, MIT Press, Cambridge,
1970; and Finney, D. J., /Statistical Method in Biologic Assays/, ed. 2,
Griffin, London, 1967.


    Digital Image Integrity

When preparing digital images, authors must adhere to the following
guidelines as stated in the CSE's White Paper on Promoting Integrity in
Scientific Journal Publications:

# No specific feature within an image may be enhanced, obscured, moved,
removed, or introduced.
# Adjustments of brightness, contrast, or color balance are acceptable if
they are applied to the entire image and as long as they do not obscure,
eliminate, or misrepresent any information present in the original.
# The grouping of images from different parts of the same gel, or from
different gels, fields, or exposures must be made explicit by the
arrangement of the figure (e.g., dividing lines) and in the figure legend.

Deviations from these guidelines will be considered as potential ethical
violations.

Note that this is an evolving issue, but these basic principles apply
regardless of changes in the technical environment. Authors should be
aware that they must provide original images when requested to do so by
the Editor-in-Chief who may wish to clarify an uncertainty or concern.

[Please see paper of Rossner and Yamada (Journal of Cell Biology, 2004,
166:11-15), which was consulted in developing these policy issues, for
additional discussion, and the CSE's White Paper on Promoting Integrity
in Scientific Journal Publications, published by the Council of Science
Editors, 2006.]


    Publication and Production Guidelines


      Proofs and Reprints

Proofs and a reprint order form are sent to the corresponding author
unless the Editorial Office is advised otherwise. The author should
designate by footnote on the title page of the manuscript the name and
address of the person to whom reprint requests should be directed.
Questions about reprints should be referred to Cadmus Professional
Communications at 410-819-3912 (direct) or 800-407-9190 (toll-free).


      Page and Color Charges

There is no submission fee for The Endocrine Society journals.

There will be a charge of $90 per printed page in the journal. There
will be a charge of $225 per color figure for members of The Endocrine
Society if they are the first or last author on the paper, and $700 per
color figure for non-members. Authors must submit usable digital art
that passes Cadmus's Rapid Inspector. Queries on page charges may be
directed to Joy Carter at Cadmus Professional Communications
(410-691-6439; fax 410-684-2792).


      Rapid Electronic Publication (REP)

Accepted manuscripts will be posted online, as submitted, generally
within a week of acceptance without copyediting, reformatting, or
corrections. These manuscripts are citable by a unique DOI (Digital
Object Identifier), which will also appear in the final printed article.
Authors will still make corrections for the copyedited manuscript that
will appear in print and in the final online version. When the final
version of the article is published in print, it will also be published
online and will replace the REP version. The REP version will be
archived and will remain available for reference.


      Editorial Office Archiving Procedures

The editorial office will retain all manuscripts and related
documentation (correspondence, reviews, etc.) for 12 months following
the date of publication or rejection.


      Institutional Repositories and NIH Deposits

Authors may archive their Rapid Electronic Publication (REP) manuscript
PDF in their institutional archive as well as PMC, UKPMC, and other PMCI
repositories immediately upon publication - no delay is required.
Authors may not use the PDF of the final, typeset version for this purpose.

To ensure that your article is cited properly, it is important that you
download the PDF of the manuscript from the journal's online web site
because the title page of the PDF is stamped with the necessary citation
information. Otherwise, users will not be able to provide the
information needed for citation tracking.

The Endocrine Society has signed an agreement with the National
Institutes of Health (NIH) that creates a new option to comply with the
NIH policy on enhanced access. This program will remove the current
burden for authors to submit their manuscripts to PubMed Central. As a
result of TES' participation in this program, all authors who published
NIH-funded articles have no obligation to submit manuscripts to the NIH
archive because TES will do this on their behalf.


    Standard Abbreviations

All nonstandard abbreviations in the text must be defined immediately
after the first use of the abbreviation. The list of *Standard
Abbreviations* <http://mend.endojournals.org/misc/abbr.shtml> is given
in the link.


    Nomenclature of Steroids

1. /Steroids/ should be named, wherever possible, according to the
IUPAC-IUB 1971 Definitive Rules for Steroid Nomenclature (/Pure Appl
Chem/ 31:285-322, 1972).
2. Trivial names may be used but, with the exception of cholesterol,
estrone, 17?-estradiol, estriol, aldosterone, androsterone,
etiocholanolone, dehydroepiandrosterone, 5?-dihydrotestosterone,
testosterone, androstenedione, pregnenolone, progesterone,
corticosterone, deoxycorticosterone, cortisone, cortisol, must be
defined systematically in a single footnote. This footnote should also
contain the definitions of all letter abbreviations.
3. Trivial names may be modified by prefixes indicating substituents (as
in 17-hydroxyprogesterone for 17-hydroxy-4-pregnene-3,20-dione), double
bonds (as in 7-dehydrocholesterol for 5,7-cholestadien-3?-ol) and
epimeric configurations of functional groups provided the locus of
epimerization is indicated (as in 3-epiandrosterone for
3?-hydroxy-5?-androstan-17-one).


    Nomenclature of Vitamin D Metabolites: Analogous and Structurally
    Related Compounds

vitamin D3, cholecalciferol
vitamin D2, ergocalciferol 25-hydroxyvitamin D3,
25-hydroxycholecalciferol, 25OHD3 25-hydroxyvitamin D2,
25-hydroxyergocalciferol, 25OHD2 25-hydroxyvitamin D, D3, D2
unspecified, 25-OHD 1,25-dihydroxyvitamin D3,
1,25-dihydroxycholecalciferol, 1,25-(OH)2D3 1,24,25-trihydroxyvitamin
D3, 1,24,25-trihydroxycholecalciferol, 1,24,25-(OH)3D3
24,25-dihydroxyvitamin D3, 24,25-dihydroxycholecalciferol, 24,25-(OH)2D3
25,26-dihydroxyvitamin D3, 25,26-dihydroxycholecalciferol, 25,26-(OH)2D3
1,25-dihydroxyvitamin D2, 1,25-dihydroxyergocalciferol, 1,25-(OH)2D2
1,25-hydroxyvitamin D, D3, D2 unspecified, 1,25-OHD dihydrotachysterol3,
DHT3 dihydrotachysterol2, DHT2 25-hydroxydihydrotachysterol3, 25-OH-DHT3
25-hydroxydihydrotachysterol2, 25-OH-DHT2

------------------------------------------------------------------------
HOME </> 	HELP </help/> 	FEEDBACK </cgi/feedback> 	SUBSCRIPTIONS
</subscriptions/> 	ARCHIVE </contents-by-date.0.shtml> 	SEARCH
</search.dtl> 	

*Endocrinology* <http://endo.endojournals.org> 	*Endocrine Reviews*
<http://edrv.endojournals.org> 	*J. Clin. End. & Metab.*
<http://jcem.endojournals.org>
*Molecular Endocrinology* 	*Recent Prog. Horm. Res.*
<http://rphr.endojournals.org> 	*All Endocrine Journals*
<http://www.endojournals.org>

***Copyright © 2008 by The Endocrine Society </misc/terms.shtml>*
